Primary immunodeficiencies: Clinical spectrum and follow-up challenges
Main Article Content
Keywords
Cancer, Common variable immune deficiency, Immunoglobulin replacament therapy, Intravenous immunoglobulins, Subcutaneous immunoglobulins
Abstract
Primary immunodeficiencies (PIDs) are a rare group of diseases with a broad clinical spectrum. Patients usually present with infections; they may also present with autoimmunity, lymphoproliferative disorders, and/or cancers or these comorbidities may occur during the disease. We aimed to analyze the demographic and clinical characteristics of adult patients with PID and evaluate the relationship between laboratory values and comorbidities with disease and each other. This study included 55 adult PID patients receiving immunoglobulin replacement therapy. Demographic characteristics, laboratory parameters, treatment modalities, and clinical course of patients were recorded. The most common PID subtype was Common Variable Immunodeficiency. The most common initial complaints were related to the respiratory and digestive systems; 11 cancers were detected in 9 patients. None of the immunodeficiency patients with cancer were in the underweight group. IgA and platelet levels were higher in the group that developed cancer, and four patients have deceased. PIDs are multisystemic diseases. Early diagnosis and prompt treatment can lead to significant improvements in morbidity and mortality. Increased awareness and interdisciplinary cooperation are important.
References
2. Mertowska P, Smolak K, Mertowski S, Grywalska E. Unraveling the role of toll-like receptors in the immunopathogenesis of selected primary and secondary immunodeficiencies. Cells. 2023;12(16):2055. https://doi.org/10.3390/cells12162055
3. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650–7. https://doi.org/10.1182/blood-2011-09-377945
4. Ho HE, Cunningham-Rundles C. Non-infectious complications of common variable immunodeficiency: Updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol. 2020;11:149. https://doi.org/10.3389/fimmu.2020.00149
5. Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N; members of the CEREDIH French PID study group. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017;140(5):1388–1393.e8.
6. Muşabak UH, Erdoğan T. Clinical features and immunoglobulin replacement therapy outcomes of adults with common variable immunodeficiency: A single centre experience. Turk J Med Sci. 2021;51(5):2427–36. https://doi.org/10.3906/sag-2010-82
7. Carvalho KI, Melo KM, Bruno FR, Snyder-Cappione JE, Nixon DF, Costa-Carvalho BT, et al. Skewed distribution of circulating activated natural killer T (NKT) cells in patients with common variable immunodeficiency disorders (CVID). PLoS One. 2010;5(9):e12652. https://doi.org/10.1371/journal.pone.0012652
8. Ardeniz O, Başoğlu OK, Günşar F, Unsel M, Bayraktaroğlu S, Mete N, et al. Clinical and immunological analysis of 23 adult patients with common variable immunodeficiency. J Investig Allergol Clin Immunol. 2010;20(3):222–36.
9. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85. https://doi.org/10.1182/blood-2007-06-091744
10. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547–54. https://doi.org/10.1086/587669
11. Patuzzo G, Mazzi F, Vella A, Ortolani R, Barbieri A, Tinazzi E, et al. Immunophenotypic analysis of B lymphocytes in patients with common variable immunodeficiency: identification of CD23 as a useful marker in the definition of the disease. ISRN Immunology. 2013;201:512527. https://doi.org/10.1155/2013/512527
12. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: Division into distinct clinical phenotypes. Blood. 2008;112(2):277–86. https://doi.org/10.1182/blood-2007-11-124545
13. Schütz K, Alecsandru D, Grimbacher B, Haddock J, Bruining A, Driessen G, et al. Imaging of bronchial pathology in antibody deficiency: Data from the European Chest CT Group. J Clin Immunol. 2019;39(1):45–54. https://doi.org/10.1007/s10875-018-0577-9
14. Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: Respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM. 2002;95(10):655–62. https://doi.org/10.1093/qjmed/95.10.655
15. Tak Manesh A, Azizi G, Heydari A, Kiaee F, Shaghaghi M, Hossein-Khannazer N, et al. Epidemiology and pathophysiology of malignancy in common variable immunodeficiency? Allergol Immunopathol (Madr). 2017;45(6):602–15. https://doi.org/10.1016/j.aller.2017.01.006
16. Ballow M, Sánchez-Ramón S, Walter JE. Secondary immune deficiency and primary immune deficiency crossovers: Hematological malignancies and autoimmune diseases. Front Immunol. 2022;13:928062. https://doi.org/10.3389/fimmu.2022.928062
17. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105. https://doi.org/10.1038/nrdp.2017.105
18. Cui M, Huang J, Zhang S, Liu Q, Liao Q, Qiu X. Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. Front Immunol. 2021;12:613530. https://doi.org/10.3389/fimmu.2021.613530
19. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–S46. https://doi.org/10.1016/j.jaci.2016.09.023
20. Kiaee F, Azizi G, Rafiemanesh H, Zainaldain H, Sadaat Rizvi F, Alizadeh M, et al. Malignancy in common variable immunodeficiency: A systematic review and meta-analysis. Expert Rev Clin Immunol. 2019;15(10):1105–13. https://doi.org/10.1080/1744666X.2019.1658523
21. Wehr C, Houet L, Unger S, Kindle G, Goldacker S, Grimbacher B, et al. Altered spectrum of lymphoid neoplasms in a single-center cohort of common variable immunodeficiency with immune dysregulation. J Clin Immunol. 2021;41(6):1250–65. https://doi.org/10.1007/s10875-021-01016-4
22. Yu H, Xu N, Li ZK, Xia H, Ren HT, Li N, et al. Association of ABO blood groups and risk of gastric cancer. Scand J Surg. 2020;109(4):309–13. https://doi.org/10.1177/1457496919863886
23. Abegaz SB. Human ABO blood groups and their associations with different diseases. Biomed Res Int. 2021;2021:6629060.0020. https://doi.org/10.1155/2021/6629060
24. Yang H, Yan J. A systematic review of prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. Medicine (Baltimore). 2022;101(39):e30893. https://doi.org/10.1097/MD.0000000000030893
25. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: Results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315–22. https://doi.org/10.1007/s10875-011-9511-0
26. Esenboga S, Çagdas Ayvaz D, Saglam Ayhan A, Peynircioglu B, Sanal O, Tezcan I. CVID associated with systemic amyloidosis. Case Reports Immunol. 2015;2015:879179. https://doi.org/10.1155/2015/879179